MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-12629

  1. 4,490 Posts.
    lightbulb Created with Sketch. 346
    Shock horror, MSB's saviour has links to big pharma that could scuttle his appointment.

    Also, more bad news:

    "Updated Jan 13, 2022 – 5.39pm, first published at 1.04pm
    Share
    Famed short-seller John Hempton has vowed to target an Australian market that is ripe with “frauds”, a problem that he says is exacerbated by a misguided corporate watchdog. Mr Hempton said Australia’s defamation laws – paired with an increase in investing activity by retail punters cashed-up with superannuation, and the Australian Securities and Investments Commission’s new habit of intimidating “completely honest short-sellers” – has resulted in an easy environment for “scammers” to sell “garbage” to mum and dad investors.

    In his most recent annual letter for his $400 million Amalthea Fund, Mr Hempton told investors the hedge fund “may bend our short book towards Australia in a few months”. " AFR
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.